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Abstract Purpose: Activation of signal transducers and activators of transcription 3 (STAT3) has been
identified as a central mediator of melanoma growth and metastasis. We hypothesized
that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the
melanoma metastasis to brain, a site typically refractory to therapies.
Experimental Design:The antitumor activities and relatedmechanisms ofWP1066were inves-
tigated both in vitro on melanoma cell lines and in vivo on mice with subcutaneously syngeneic
melanoma or with intracerebral melanoma tumors.
Results:WP1066 achieved an IC50 of 1.6, 2.3, and1.5 Amol/L against melanoma cell lineA375,
B16, and B16EGFRvIII, respectively.WP1066 suppressed the phosphorylation ofJanus-activated
kinase 2 and STAT3 (Tyr705) in these cells. Tumor growth in mice with subcutaneously estab-
lished syngeneic melanoma was markedly inhibited byWP1066 compared with that in controls.
Long-term survival (>78 days) was observed in 80% of mice with established intracerebral
syngeneic melanoma treatedwith 40mg/kg ofWP1066 in contrast to controlmicewho survived
for a median of 15 days. AlthoughWP1066 did not induce immunologic memory or enhance
humoral responses to EGFRvIII, this compound reduced the production of immunosuppressive
cytokines and chemokines (transforming growth factor-h, RANTES, MCP-1, vascular endothelial
growth factor), markedly inhibited natural and inducible Treg proliferation, and significantly
increased cytotoxic immune responses ofTcells.
Conclusions: The antitumor cytotoxic effects of WP1066 and its ability to induce antitumor
immune responses suggest that this compound has potential for the effective treatment of
melanoma metastatic to brain.
Melanoma is a common and deadly tumor that despite the
development of new therapeutic strategies, upon metastasis to
the brain, is associated with a median survival time of <1 year.
Furthermore, stage IV patients with brain metastasis are almost
always excluded from participation in clinical trials. The Janus
kinases (JAK)/signal transducers and activators of transcription
(STAT)3 pathway is one of the key signaling pathways that
drives the fundamental components of melanoma malignancy.
The STAT3 protein is overexpressed in most cancers, including
melanoma, and fosters tumorigenesis by preventing apoptosis
(increases levels of the antiapoptotic proteins survivin, BCL-XL,
and MCL1), enhancing proliferation (increases c-Myc and
cyclin D1/D2 levels), angiogenesis [increases levels of vascular
endothelial growth factor (VEGF) and hypoxia inducible
factor], invasiveness (increases levels of matrix metalloprotei-
nase 2 and matrix metalloproteinase 9), and metastasis (1, 2).
Xie et al. (3) have shown that only highly metastatic melanoma
cell lines, rather than poorly metastatic subtypes, overexpress
matrix metalloproteinase 2, and have elevated levels of
activated STAT3. Furthermore, blockade of activated STAT3
through expression of a dominant-negative STAT3 significantly
suppresses invasiveness of the tumor cells, inhibits tumor
growth, and prevents metastasis in nude mice. These studies
indicate that STAT3 activation might be the crucial event in the
development of melanoma metastasis.
STAT3 in the JAK/STAT pathway transduces extracellular
signals such as cytokines and growth factors. The EGF receptor
(EGFR) and interleukin 6 activate JAK, which subsequently
activates STAT by phosphorylation of the tyrosine residue in
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its transactivation domain. The EGF variant III (EGFRvIII) is
constitutively active, with a cytoplasmic domain identical to
that of the wild-type EGFR. The EGFR has been shown to
physically interact with STAT3 (4, 5), and the phosphorylation
of STAT3 has been attributed exclusively to EGFRvIII (6, 7),
although this is controversial (8).
WP1066, a novel low molecular weight agent, has been
shown to effectively block constitutively activated STAT3, JAK2/
STAT3 activation by cytokines, and STAT5 (9–14) and to
induce c-Myc degradation in multiple hematologic tumor cell
types (15, 16). A recent study showed that treatment with
WP1066 effectively inhibited the STAT3 pathway in glioma
cell lines (U87-MG and U373-MG), down-regulated the
antiapoptotic targets of STAT3 (BCL-XL, MCL-1, and c-Myc),
and activated BCL2-associated X protein. WP1066 was found to
increase the percentage of glioma cells undergoing apoptosis in
a dose-dependent manner. Furthermore, in a murine subcuta-
neous model of malignant glioma, mice repeatedly injected
i.p. with WP1066 (40 mg/kg) showed a significant inhibition
in the growth of the tumors generated from U87-MG cells (12).
STAT3 has recently been hypothesized to be a key regulator
of immunosuppression in cancer patients and is therefore
considered a potential target for immunotherapy (17, 18). A
pharmacologic agent capable of achieving physiologically
relevant central nervous system (CNS) concentrations that is
also able to restore or improve the immune responses of
patients while exerting direct tumor cytotoxicity, would be
highly desirable. We have recently shown that WP1066 can
penetrate the CNS in mice and, in physiologically relevant
doses in vitro , reverse tolerance in immune cells isolated from
glioblastoma multiforme patients (19). WP1066 activates the
immune system by inducing expression of costimulatory mole-
cules, stimulating the production of the immune-stimulatory
cytokines, and inducing T-cell effector responses, even in cancer
patients who are refractory to the CD3 stimulation (19). The
immune activation induced by WP1066 correlated with the
phosphorylation of the respective tyrosine kinases Syk (Tyr352)
in monocytes and ZAP-70 (Tyr319) in T cells. The combination
of antitumor cytotoxic effects, the induction of antitumor
immune responses, easy oral administration, and excellent CNS
penetration provided compelling rationale for testing WP1066
against a variety of cancers, but especially against melanoma,
which is dependent on STAT3, has been frequently targeted
with immunotherapy (20), and frequently involves the CNS.
Materials andMethods
Tumor cell lines and murine models . The B16/F10 murine melanoma
cell line was derived from a spontaneous melanoma in the C57BL/6J
mouse of the H-2B background and was provided by Dr. Isaiah
Fidler [The University of Texas M. D. Anderson Cancer Center (M. D.
Anderson), Houston, TX]. The B16 cell line was stably transfected with
the mouse EGFRvIII (kindly provided by Dr. Darrell Bigner of Duke
University Medical Center, Durham, NC) to produce B16EGFRvIII cells,
which provide an immunologic target for assessment of antigen-specific
induced immune responses (21). The EGFRvIII expressed in these B16
cells is the murine equivalent of the human form of the receptor and is
syngeneic within the B16/F10 model system. A375 is a human
melanoma cell line that was provided by Dr. Elizabeth Grimm (M. D.
Anderson, Houston, TX). The B16EGFRvIII cells were grown in
Improved MEM Zinc Option medium (Life Technologies Bethesda
Research Laboratories/Invitrogen) containing 10% fetal bovine serum.
The B16 and A375 cell lines were maintained in RPMI 1640
supplemented with 10% fetal bovine serum at 37jC in a humidified
atmosphere of 5% CO2 and 95% air. All cell lines were grown in
antibiotic-free medium and were free ofMycoplasma contamination (22).
For the in vivo experiments, we used 4- to 6-wk-old female C57BL/6J
mice strictly inbred at M. D. Anderson and maintained in the M. D.
Anderson Isolation Facility in accordance with Laboratory Animal
Resources Commission standards and conducted according to an
approved protocol, 08-06-11831.
Cell proliferation/survival assay. For cell proliferation assays, A375,
B16, or B16EGFRvIII cells were seeded at a density of 2,000 cells
per well in 96-well culture plates and were treated with WP1066 at
increasing concentrations of 0, 0.155, 0.3125, 0.625, 1.25, 2.5, 5.0, and
10 Amol/L. After 72 h of treatment, 25 mL of 5 mg/mL dimethyl
thiazolyl diphenyl tetrazolium salt (Sigma-Aldrich) solution were
added to each well, and the cells were cultured for 3 h at 37jC in a
humidified atmosphere of 5% CO2 and 95% air. The cells were lysed
with 100 AL per well of lysing buffer [50% dimethylformamide, 20%
SDS (pH 5.6)] and incubated at room temperature overnight. Cell
proliferation and viability were evaluated by reading the absorbance at
570 nm, and the IC50 was calculated.
Immunoprecipitation and immunoblotting analysis. Cells were rinsed
with ice-cold PBS and lysed in cell culture plates for 30 min in ice-cold
lysis buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1 mmol/L
EDTA, 1% Triton-X-100, 1 mmol/L phenylmethylsulfonyl fluoride,
10 Ag/mL leupeptin, 10 Ag/mL aprotinin, and 1 mmol/L sodium
vanadate]. The lysates were centrifuged at 14,000 rpm for 10 min at
4jC. The supernatants were collected and quantified for protein con-
tent. Equal amounts of proteins were electrophoretically fractionated in
8% SDS-polyacrylamide gels, transferred to nitrocellulose membranes,
and subjected to immunoblot analysis with specific antibodies against
phospho-STAT3 (Tyr705), total STAT3, c-Myc, phospho-AKT (Ser473),
survivin (Cell Signaling Technology, Inc.), and h-actin (Sigma-Aldrich),
respectively. In addition, the transferred membranes from B16 and
B16EGFRvIII cell lysates were immunoblotted with a specific antibody
against EGFRvIII (from Dr. Darrell Bigner, Duke University Medical
Center, Durham, NC). Autoradiography of the membranes was done
using Amersham enhanced chemiluminescence Western blotting
detection reagents (Amersham Biosciences). For immunoprecipitation
and immunoblotting analysis of phospho-JAK2, antiphosphotyrosine
4G10 (Upstate Biotechnology, Inc.) conjugated to agarose beads was
used for immunoprecipitation, and anti-JAK2 antibody (Cell Signaling
Technology, Inc.) was used for Western blotting.
Translational Relevance
Development of new, effective therapies for metastatic
melanoma that target novel pathways associated with the
genesis of metastatic disease is a major unmet clinical
need. Constitutive activation of STAT3 has been shown in
a variety of human malignancies, including melanoma.
We have designed and synthesized a series of potential
inhibitors of the Janus-activated kinase/STAT3 pathway
and identified a lead compound,WP1066, displaying high
activity within in vivo models. In the study described here,
we testedWP1066 inmurine models of established central
nervous system melanoma, a site typically refractory to
therapies, and showed marked in vitro and in vivo activity.
A key mechanism of activity of WP1066 includes the
enhancement of cytotoxicT-cell responses and inhibition
of regulatory T cells. Based on these preclinical data,
WP1066 has therapeutic potential for the treatment of
melanoma including intracerebral metastasis and as an
immune therapy.
Cancer Therapy: Preclinical
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In vivo antitumor activity. To induce the subcutaneous tumors,
logarithmically growing B16EGFRvIII cells were injected into the right
hind flank of C57BL/6J mice at a dose of 1.0  104 cells suspended in
100 AL of PBS. Tumors were measured every other day. Mice showing
signs of morbidity were immediately euthanized according to the M. D.
Anderson guidelines. Tumor volume was calculated with slide calipers
using the following formula: V = (L  W  H)/2, where V is volume
(mm3), L is the long diameter, W is the short diameter, and H is the
height.
To induce intracerebral tumors in C57BL/6J mice, B16 or B16EGFR-
vIII cells were collected in logarithmic growth phase, washed twice
with PBS, mixed with an equal volume of 10% methyl cellulose in
Improved MEM Zinc Option medium, and loaded into a 250-AL syringe
(Hamilton) with an attached 25-gauge needle. The needle was
positioned 2 mm to the right of bregma and 4 mm below the surface
of the skull at the coronal suture using a stereotactic frame (Kopf
Instruments). The intracerebral tumorigenic dose for the B16 or
B16EGFRvIII cells was 5  102 in a total volume of 5 AL. Tumor
rechallenge was done on mice surviving beyond 78 d (long-term
survivors) by using the same cell dose and implantation coordinates
in the contralateral hemisphere. Control naBve mice were challenged
at the same time to verify the viability of the tumor rechallenge.
WP1066 was synthesized and supplied by a co-author (W.P.). It was
dissolved in a mixture of 20 parts DMSO to 80 parts polyethylene glycol
300 (Sigma-Aldrich) at titered concentrations and delivered in a final
volume of 100 AL. Before use, WP1066 was stored as a lyophilized
powder at 4jC. Treatment was started 16 d after establishment of
subcutaneous tumors and 3 d after intracerebral implantation, with
titered doses of WP1066 injected i.p. or by oral gavage (o.g.) in a vehicle
of DMSO/polyethylene glycol 300 (20 parts/80 parts) on a once per day
schedule (5 d on, 2 d off). Ten mice per experimental group were used,
including treatement with the DMSO/polyethylene glycol 300 vehicle
alone in the control group.
Toxicity. Toxicity to female C57BL/6J mice was monitored by
weighing them every other day, performing daily neurologic examina-
tions on them consisting of monitoring stepping and placing reflexes,
and histologic examination of the brain and systemic organs. The brain
and systemic organs were assessed by immunohistochemistry and
evaluated in a blinded fashion relative to treatment groups by
subspecialty pathologists at the M. D. Anderson.
Quantification of cytokines and chemokines. B16 and B16EGFRvIII
cells were seeded in 6-well culture plates at a density of 2  105 in 2 mL
of complete cell culture medium per well and incubated overnight at
37jC. The next day, cells were treated with WP1066 at titered
concentrations and incubated for 24 h at 37jC in a humidified
atmosphere containing 5% CO2 and 95% air. Supernatants were then
collected and stored at -20jC for the measurement of TGF-h1 and VEGF
concentrations using ELISA kits according to the manufacturer’s
instructions (R&D Systems). Briefly, the latent transforming growth
factor (TGF)-h1 in the supernatants was first activated and neutralized
to make it detectable by the immunoassay and then added in duplicate
to precoated culture plates and incubated for 2 h at room temperature.
After washing, horseradish peroxidase–conjugated detection antibody
was added to each well and culture plates were incubated for another
2 h at room temperature. Finally, tetramethylbenzidine was added as
substrate for color development. The absorbance was measured at
450 nm with a microplate reader (Spectra Max 190; Molecular Devices),
and TGF-h1 and VEGF concentrations were quantified with the
SoftMax Pro software (Molecular Devices). The detection limit for
TGF-h1 ranged from 1.7 to 15.4 pg/mL and, for VEGF, from 125 to
2,000 pg/mL, with a lower limit of detection of 5 pg/mL. Concen-
trations of MCP-1 and RANTES were determined with multiplexed
ELISA done by Quansys Biosciences (Quansys Biosciences). The
detection limit for MCP-1 ranged from 15.6 to 1,000 pg/mL and, for
RANTES, from 6.3 to 400 pg/mL.
EGFRvIII-specific humoral responses. Serum was obtained from the
mice and stored at -20jC before analysis in a PEP-3-Dynabead assay.
PEP-3, the 14-mer peptide that spans the mutated splice junction of
EGFRvIII, was covalently linked to magnetic microspheres according
to the manufacturer’s instructions (Invitrogen). Briefly, the Dynabeads
were incubated overnight in borate buffer (pH 9.5) with PEP-3 at 37jC
on an end-over-end mixer. The following day, Dynabeads were washed
and incubated an additional 2 h at 37jC in 0.1 mol/L Tris (pH 9) to
further block any active sites. The final product was adjusted to 2  108
beads per mL with PBS + 0.1% bovine serum albumin + 0.25% sodium
azide and stored at 2jC to 8jC.
Approximately 1  105 PEP-3 Dynabeads were added to the serum
samples and incubated on a vortex mixer for 30 min at room
temperature. Dynabeads were washed and further incubated with
phycoerythrin-labeled goat-anti-mouse (1:100) for an additional
30 min. After washing away excess goat-anti-human-phycoerythrin,
the Dynabeads were analyzed on a flow cytometer. All serum samples
were initially diluted 1:100 with PBS + 0.1% Tween 20 and assayed
in triplicate. To determine specificity, an additional sample set was
preincubated for 15 min with 500 ng of the PEP-3 peptide to block any
anti –PEP-3 that would be captured by the PEP-3– conjugated
Dynabeads. The same criteria were used to establish equivalent binding
units per milliliter (relative to nanogram of an anti-EGFRvIII mono-
clonal antibody L8A4 per milliliter) as previously described for human
serum samples (23). The mean fluorescence intensit had to be at least
3.12, and the signal had to be at least 15% blocked by preincubation
with free PEP-3. If the results met these criteria, the estimated binding
Table 1. Systemic histopathologic effects of WP1066 in C57BL/6 mice
Drug Administration
Route
Total
(mg/kg)
Pathology of systemic organs
Spleen Thymus Lung Heart Kidney Brain Liver GI
Vehicle i.p. N/A 1/10*, 2/10c 0/8 0/9 0/10 0/10 0/10 1/10 4/10b
WP1066 i.p. 20 4/5c 0/7 1/7* 1/7x 2/7* 0/7 4/7* 1/6*, 2/6b
WP1066 i.p. 10 4/10c 0/8 1/10ck 1/10* 3/10* 0/10 1/10{, 2/10* 1/9*, 1/9b
Vehicle o.g. N/A 3/10c 1/8* 0/10 0/10 0/10 0/10 0/10 1/10*
WP1066 o.g. 40 0/5 0/5 0/5 0/4 1/5 0/5 1/5**,2/5* 0/4
Abbreviation: N/A, not applicable.
*Autolysis.
cHemosiderin staining within macrophages.
bReactive lymphoid follicles with germinal center.
xLikely postmortem bacterial endocarditis.
kPulmonary congestion.
{Chronic inflammatory infiltrate in connective tissue adjacent to the liver.
**Chronic inflammation.
STAT3 Blockade inMelanoma
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units were extracted from the L8A4 standard curve. Standards of mouse
anti–PEP-3 antibody (L8A4 per milliliter) were run with each assay and
negative (normal serum) controls. The cytometer was standardized each
day with phycoerythrin–fluorescence-activated cell sorting microbeads
and unreacted PEP-3 Dynabeads.
Ex vivo T-cell cytotoxicity assays. Groups of nontumor-bearing
animals were vaccinated with 100 Ag of PEP-3-keyhole limpet
hemocyanin (KLH) in a 1:1 ratio with complete Freund’s adjuvant
(CFA), 100 Ag of PEP-3-KLH, 40 mg/kg of WP1066, or 100 Ag of PEP-3-
KLH with 40 mg/kg of WP1066, every 2 wk, for a total of 4 doses. Other
than WP1066 (o.g.), the vaccinations were administered to the base of
the tail, right groin, left groin, and flank, respectively. Standard assays
were used to determine the percentage of cytolysis of the B16EGFRvIII
cells by splenocytes obtained from C57BL/6J mice 48 h after the last
vaccination (22). Splenocytes obtained from naBve C57BL/6J mice were
used as negative controls.
Regulatory T-cell suppression assays. Single-cell suspensions were
prepared from pooled lymph nodes and spleens of C57BL/6J mice. The
CD4+ cells were enriched using CD4 MACS beads (Miltenyi Biotec) and
were stained with peridinin-chlorophyll-protein complex– labeled anti-
CD4 (L3T4), FITC-labeled anti-CD62L (MEL-14), and allophycocyanin-
labeled anti-CD25 (PC61). They were further sorted on a FACSAria cell
sorter (BD Biosciences) to obtain pure populations of CD4+CD25-
CD62Lhi naBve T cells and CD4+CD25+ natural regulatory T cells
(Treg). NaBve CD4+CD25-CD62Lhi cells were then incubated on anti–
CD3-coated plastic plates (2 Ag/mL) in complete RPMI 1640 with
soluble anti-CD28 (2 Ag/mL) and rTGF-h1 (1 ng/mL) to induce Foxp3+
Tregs. CD4+CD25+ natural Tregs were stimulated with anti-CD3–
coated plastic plates (2 Ag/mL) and soluble anti-CD28 (2 Ag/mL). The
cultures were supplemented with WP1066 at concentrations of 0, 0.1,
and 1.0 Amol/L, respectively. Peridinin-chlorophyll-protein complex–
conjugated anti-CD4 (L3T4) and allophycocyanin-conjugated anti-
CD25 (PC61) monoclonal antibodies were used for cell surface
staining. To detect FoxP3 protein expression, the surface-stained cells
were further subjected to intracellular staining with phycoerythrin-
conjugated monoclonal antibodies to mouse FoxP3 (clone FJK-16s;
eBioscience) using staining buffers and conditions specified by the
manufacturer.
Treg detection in human melanoma brain metastases and peritumoral
CNS tissue . Fresh human tumors and peritumoral tissue were
obtained from patients undergoing surgical resection for melanoma
metastasis to the brain. The tumor and peritumoral tissue was
identified and separated by an experienced neurosurgeon (A.B.H.)
before submission to the laboratory. The analysis of the tissue was
conducted under protocol # LAB03-0687, which was approved by
the institutional review board at M. D. Anderson, and informed
consent was obtained. Tissues were transported on ice from the
operating room and were mechanically dissociated in the laboratory.
Red cell lysing buffer was added to the cell suspensions before washing
them with PBS. Cells were transferred to a 96-well culture plate
and stained for surface markers using human allophycocyanin-labeled
anti-CD4 and phycoerythrin-labeled anti-CD25 antibodies (BD
Biosciences). Cells were then fixed and made permeable before
intracellular FoxP3 staining with human FITC-labeled anti-FoxP3
(eBioscience) as described previously (24).
Statistical analysis . Kaplan-Meier product-limit survival probability
estimates of overall survival were calculated (25), and log-rank tests
(26) were done to compare overall survival between treatment groups
and the control arm. For the tumor growth data set, at each time point
when the mice were measured, since 2 cages of mice used either for
treatment arm or for control arm, respectively, the nested two-factor
model was used to assess the effect of drug treatment and cage by
the formula: yijk = u . + ai + h j(i) + qijk where i = 1, 2 (treatment and
control arm); j = 1, 2 (cage); and k is the indicator of mice within cage
(arm) combination. The difference in mean tumor growth between the
treatment and control arms (ai) was compared. For all the repeated
tumor measurements of mice over time, the mixed model was used
(27) and assessed by the formula: yijk = u + ai + dij + H k + (a H )ik + qijk
where i = 1, 2 (treatment and control arm); j is the indicator of mice
within cage (arm) combination; and k = time k for tumor
measurement; where dij and qijk are normally independently distributed
(NID) with dij f NID (0, j 2s) and qijk f NID (0, j2q). A P value of
Fig. 1. Western blot analyses showing that
WP1066 suppresses the intracellular
signaling of p-JAK2, p-STAT3, c-Myc, and
survivin inmelanoma cells.A, A375, B16, or
B16EGFRvIII cells were cultured with either
medium alone or medium supplemented
with 5 Amol/L ofWP1066 for 2 h. Cell
lysates were prepared and quantified for
protein content. A total of 40 Ag protein
from each sample was used for
immunoprecipitation and immunoblotting
analysis of phospho-JAK2.
Antiphosphotyrosine 4G10 conjugated to
agarose beads was used for
immunoprecipitation, and anti-JAK2
antibody was used forWestern blotting.
B, A375 cells were incubated withWP1066
at concentrations of 0, 1.25, 2.5, and 5
Amol/L for 2 h. C, B16 or B16EGFRvIII cells
were cultured with either medium alone or
medium supplemented with 5 Amol/L of
WP1066 for 2 h. D, B16EGFRvIII cells were
cultured with 5 Amol/L ofWP1066 for 0, 2,
4, 8, 12, and 24 h. A total of 20 Ag protein
was electrophoretically fractionated in 8%
SDS-polyacrylamide gels, transferred to
nitrocellulose membranes, and followed by
immunoblot analysis with specific
antibodies against phospho-STAT3
(Tyr705), total STAT3, c-Myc, survivin, and
h-Actin. In addition, the transferred
membranes from B16 and B16EGFRvIII cell
lysates were immunoblotted with a specific
antibody against phospho-Akt (Ser473)
or EGFRvIII.
Cancer Therapy: Preclinical
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V0.05 was considered statistically significant. The in vitro cytotoxicity
was analyzed using the unpaired standard Student’s t test.
Results
Toxicity. To define the maximum tolerated dose, a single
titered dose of WP1066 was administered i.p. to mice with severe
combined immunodeficiency mice. At a dose of 120 mg/kg,
symptoms of acute toxicity included diarrhea and a high
frequency of urination. Chronic toxicity (at 3 months),
including adhesion of the mouse intestine to the abdominal
wall and muscle and death was observed in 1 of 5 mice.
Further escalation of the dose to 140 mg/kg resulted in the
death of 3 of 5 mice in the same interval. Neither acute nor
chronic toxicity was observed in the vehicle (control) group.
When injections of 50 mg/kg were delivered once per day for
5 days (with a rest for 2 days) for a total of 2 weeks, acute
toxicity was observed in 1 of 8 mice, and chronic toxicity was
observed in 2 of 8 in the treated group; thus, 40 mg/kg once per
day, 5 times per week was selected as the maximal dose of
WP1066, in which severe combined immunodeficiency mice
did not have either acute or chronic toxicity. Within immune
competent C57BL/6J mice, the maximum tolerated dose of
WP1066 delivered i.p. was 20 mg/kg. When the dose of 40 mg/
kg was delivered by tail vein injection in mice every other day
for a total of five injections, there was marked inflammation
and sclerosis of the vessel. In contrast, when doses of up
to 120 mg/kg were administered every other day by o.g.
for 8 doses and 180 mg/kg for 5 doses, no acute or chronic
toxicity symptoms were observed. An maximum tolerated
dose for o.g. in C57BL/6J mice could not be established above
40 mg/kg.
The spleens, kidneys, lungs, hearts, and brains of C57BL/6J
mice treated with WP1066 underwent a detailed histologic
examination by a pathologist blinded to the treatment group.
No significant abnormalities were found in these mice (Table 1).
Because WP1066 is an immune activator, nonspecific immune
reactivity remains a consideration. Therefore, Luxol fast blue
staining was conducted on the CNS axis to determine if there
was evidence of induction of autoimmunity. No focal plaques
of demyelination or significant macrophage infiltration were
observed in areas without tumor in any animal treated with
WP1066.
WP1066 inhibits growth of melanoma cell lines in vitro. To
determine if there was a direct cytostatic effect of WP1066 on
the growth of B16, B16EGFRvIII, or A375 cells, these cell
lines (in logarithmic growth) were exposed to WP1066 at
concentrations of 0, 0.155, 0.3125, 0.625, 1.25, 2.5, 5.0, and
10 Amol/L. After 72 h, the dimethyl thiazolyl diphenyl
tetrazolium salt assay was done; the IC50s for B16, B16EGFR-
vIII, and A375 cells were 2.3, 1.5, and 1.6 Amol/L of WP1066,
respectively.
WP1066 suppresses phosphorylation of JAK2 and STAT3 . To
determine on which pathways WP1066 exerts its activity,
molecules both upstream and downstream of the STAT3
pathway were evaluated by Western blot analysis. WP1066
inhibited the phosphorylation of JAK2 in all three melanoma
cell lines tested (Fig. 1A). In human melanoma cell line
A375, WP1066 inhibited the phosphorylation of STAT3 and
decreased the level of c-Myc in a dose-dependent manner
(Fig. 1B). The inhibition of phosphorylated STAT3 (p-STAT3)
by WP1066 in the murine melanoma cell lines B16 and
B16EGFRvIII seemed weaker than for A375 cells (Fig. 1C).
When the B16 melanoma line was stably transfected with the
murine equivalent of EGFRvIII, which is the constitutively
active variant of EGFR, overall, STAT3 did not seem to be
appreciably up-regulated (Fig. 1C). In the B16EGFRvIII cell
line, WP1066 did not affect p-Akt of the JAK/PI3K/AKT/
mammalian target of rapamycin pathway, but it decreased
the level of c-Myc and survivin in a time-dependent manner
(Fig. 1D).
Treatment with WP1066 suppresses the growth of subcutaneous
melanoma . To determine whether treatment with WP1066
would retard the formation of subcutaneous tumors in a
syngeneic system, C57BL/6J mice were injected with B16EGFR-
vIII cells and then treated on day 16 withWP1066, when tumors
were grossly evident. Subcutaneous tumor growth progressed in
all of the C57BL/6J mice treated with the vehicle control. For
example, in one experiment, the mean cross-sectional areas of
the tumors in the control group on days 18, 20, 23, and 25
were 169 F 71, 352 F 149, 980 F 309, and 1,294 F 621 mm2,
respectively. In contrast, in the WP1066-treated group, the mean
cross-sectional areas were 100 F 54 mm2 (P = 0.04; compared
with the control group), 155 F 102 mm2 (P = 0.004), 441 F
334 mm2 (P = 0.01), and 666 F 562 mm2 (P = 0.05; Fig. 2).
These data were similar in two separate experiments. WP1066
also significantly inhibited tumor growth in nude mice injected
with subcutaneous A375 cells in two independent experiments
(data not shown).
WP1066 is efficacious in the treatment of C57BL/6J mice with
established intracerebral tumors. To determine whether treat-
ment was also efficacious against established intracerebral
tumors, C57BL/6J mice with intracerebral tumors from
B16EGFRvIII cells were treated with WP1066 (i.p and o.g.)
starting on day 3 after tumor cell implantation. The median
survival time for the control group was 17.5 days (95%
confidence interval; 16, NA). For mice treated i.p. with 10 (n =
10) and 20 (n = 10) mg/kg of WP1066, the median survival
times were 18.5 days (95% confidence interval; 17, NA) and
23.5 days (95% confidence interval; 19, NA), respectively. This
Fig. 2. Volume of subcutaneous B16EGFRvIII tumors in C57BL/6J mice treated
with vehicle control or withWP1066 via o.g. once per day after tumors were
measurable (n = 6 per group per experiment). On day 25, a P value of < 0.05
comparing theWP1066-treated group to the vehicle control-treated group.
The figure is the result of a single experiment, but repeated twice.
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was statistically significant (P < 0.001) for mice treated with
WP1066 at the 20 mg/kg dose (Fig. 3A). For the mice treated by
o.g. with WP1066 at 40 mg/kg (n = 10), 80% survived long
term (>78 days; P < 0.0001 compared with the control group),
and there was at least a 324% increase in median survival time
when the experiment was terminated to perform the tumor
rechallenge experiments (Fig. 3B). Similar data and results were
obtained for the mice with established intracerebral B16 tumors
treated with WP1066 (Fig. 3C).
Mice treated with WP1066 do not develop immunologic
memory. To determine if mice with intracerebral tumors
treated with WP1066 were able to generate long-lasting
protection against tumor regrowth, mice that survived for
78 days after the initial tumor cell implantation were
reinoculated with B16EGFRvIII cells but in the contralateral
hemisphere. Upon this rechallenge, in the animal group that
had received WP1066 via o.g., the median survival time was
18 days (95% confidence interval; 17, NA), which was
significantly different from 11 days, the median survival time
of naBve animals challenged at the same time (95% confidence
interval; 10, NA; P < 0.001); however, only 10% of the mice
were long-term survivors (Fig. 3B). Similar data and results
were obtained in the survival of mice with intracerebral B16
tumors (Fig. 3C).
WP1066 inhibits the production of immunosuppressive cyto-
kines in melanoma cell lines. To determine if WP1066 could
exert an effect on the immunosuppressive and proangiogenic
properties of melanoma, B16 and B16EGFRvIII cells were
treated for 24 hours with doses of WP1066 below the IC50, the
supernatant was harvested, and the cytokine production was
determined by ELISA. Inhibition of TGF-h, the regulated on
activation normal T-expressed and secreted (RANTES) cytokine,
VEGF, and the Treg chemotaxic cytokine, MCP-1, were noted
starting at a dose of 0.01 Amol/L of WP1066 (Fig. 4).
Vaccination with WP1066 does not enhance humoral immunity.
To determine whether WP1066 enhanced humoral responses,
C57BL/6J mice vaccinated with PBS, WP1066, PEP-3-KLH,
PEP-3-KLH + WP1066, and PEP-3-KLH + CFA were examined
for humoral responses after the first and third vaccinations.
None of the animals treated with PBS (n = 3), PEP-3-KLH
(n = 3), or PEP-3-KLH + CFA (n = 3) had detectable humoral
responses to EGFRvIII after the first vaccination. EGFRvIII
humoral responses were not detected in the mice that were
vaccinated thrice with PBS (n = 5), PEP-3-KLH (n = 5), or
WP1066 alone (n = 4). As expected, mice that were vaccinated
thrice with PEP-3-KLH + CFA (n = 5) produced significant
quantities of IgG antibody, ranging from 1,156 to 10,308 ng/mL.
In contrast, mice treated with the combination of PEP-3-KLH +
WP1066 (n = 5) showed no detectable EGFRvIII antibody
responses. Furthermore, in animals (n = 8) that survived intra-
cerebral tumor treatment with WP1066, none showed the
induction of EGFRvIII-specific responses (Fig. 5A).
Vaccination with WP1066 induces T-cell cytotoxic responses.
To determine whether WP1066 enhanced cytotoxic responses
directed against PEP-3, splenocytes from naBve C57BL/6J
mice and C57BL/6J mice vaccinated with PEP-3-KLH,
WP1066, PEP-3-KLH + WP1066, and PEP-3-KLH + CFA were
stimulated in vitro with B16EGFRvIII cells, and cytotoxicity was
assessed against carboxyfluorescein succinimidyl ester–labeled
B16EGFRvIII target cells. The naBve mice showed minimal lysis
of the B16EGFRvIII target cells. The PEP-3-KLH– or WP1066-
treated mice had increased cytotoxic clearance of the B16EGFR-
vIII target cells compared with naBve mice (Fig. 5B). In mice
treated with both PEP-3-KLH and WP1066, there was further
significant enhanced cytotoxic clearance of the B16EGFRvIII
Fig. 3. Survival data from C57BL/6J mice treated withWP1066 after intracerebral
B16EGFRvIII cells or B16 cells were established in the brain. A, antitumor efficacy
was observed in mice injected i.p. withWP1066 (n = 10 per dose), but it was
dose limiting owing to localized inflammation. A comparison of survival time in the
group treated i.p. withWP1066 at 20 mg/kg with that for the vehicle control group
yielded P values of 0.027, 0.011, 0.005, 0.002, and 0.001on days 30, 35, 40, 45,
and 50, respectively. B, C57BL/6J mice with established intracerebral B16EGFRvIII
cells treated withWP1066 via o.g. (n = 10) showed at least a 324% increase in
their median survival time, and 80% achieved long-term survival compared with
those in the vehicle-treated controls (n = 10). For the group treated with 40 mg/kg
WP1066 by o.g., the P values were 0.04, 0.18, 0.007, 0.002, 0.001, and 0.001at
days 25, 30. 35, 40, 45, and 50, respectively, compared with the vehicle control
group.C, antitumor efficacy was also observed in C57BL/6Jmice with established
intracerebral B16 cells treated withWP1066 via o.g. (n = 10). In animals that
survived longer than 78 d, subsequent rechallenge by injection of tumor cells into
the contralateral hemisphere indicated that minimal immunologic memory was
induced (A-C).
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target cells compared with mice that were treated with either
WP1066 or PEP-3-KLH alone (P < 0.05; Fig. 5B).
WP1066 inhibits FoxP3 induction in peripheral T cells and
down-regulates FoxP3 in natural Tregs. To investigate the
effects of WP1066 on the peripheral induction of FoxP3+
Tregs, we used an in vitro Treg induction system in which
FoxP3 expression was induced in naBve CD4+ (CD4+CD25-
CD62Lhi) T cells isolated from the spleens of C57BL/6J mice.
FoxP3+ Treg generation was directly measured by intracellular
staining for FoxP3 protein expression. In this system, naBve
CD4+ T cells underwent robust FoxP3+ Treg differentiation
when they were activated by polyclonal stimulation in the
presence of exogenous TGF-h. In contrast, WP1066 inhibited
FoxP3+ Treg induction, compared with the control, from 70%
to 54% at a 1.0 Amol/L concentration of WP1066 (Fig. 5C).
Moreover, 1.0 Amol/L of WP1066 reduced Foxp3+ natural
Tregs to 13.8% under polyclonal stimulation (Fig. 5C). Thus,
WP1066 can diminish the induction of Tregs, which may
contribute to the antitumor responses observed with its use
in vivo .
Treg cells are present in both tumor and peritumoral tissue of
patients with melanoma metastasis to the brain. To determine if
Tregs were present within human melanoma in the CNS, we
dissected the peritumoral brain tissue from the metastatic
tumor, dissociated each respectively into a single-cell suspen-
sion, and then stained for the presence of CD4+CD25+FoxP3+
cells by flow cytometric analysis as we have previously
described (24). Both peritumoral brain isolated 1 cm from
the tumor margin and the melanoma metastasis contained
CD4+CD25+FoxP3+ Tregs, with greater numbers located
within the metastasis (Fig. 5D).
Discussion
We have designed and synthesized WP1066, an inhibitor of
the JAK2/STAT3 pathway, which showed marked in vivo efficacy
for treating established intracerebral syngeneic melanoma. The
oral administration route showed optimal efficacy and minimal
toxicity in vivo , which is desirable for continued development
and translation to human subjects. Although efficacy was
observed with i.p. or i.v. dosing, these administration routes
were limited owing to localized inflammatory responses,
specifically, peritoneal adhesions and venous sclerosis. The
assessment of systemic organs from mice that received WP1066
failed to show other significant toxicities, but more specifically
and most importantly, Luxol fast blue staining of the CNS
failed to reveal evidence of demyelination or macrophage
infiltration in areas of the CNS that did not harbor the
intracerebral tumor that would indicate the inadvertent
induction of autoimmunity. This is probably because STAT3
has been shown to be the key regulator for the generation of
Th17 cells (28, 29), which are primary immune cell mediators
Fig. 4. The production ofTGF-h, MCP-1, RANTES, andVEGF is inhibited byWP1066 at doses below the IC50. B16 and B16EGFRvIII cells in logarithmic growth were treated
with titered doses ofWP1066 for 24 h. At a dose of 0.01 Amol/LWP1066, the cytokinesTGF-h, RANTES,VEGF, and theTreg chemokine MCP-1were all inhibited, as
detected in ELISA assays.
STAT3 Blockade inMelanoma
www.aacrjournals.org Clin Cancer Res 2008;14(18) September15, 20085765
Cancer Research. 
on November 2, 2017. © 2008 American Association forclincancerres.aacrjournals.org Downloaded from 
of autoimmunity (30). Thus, WP1066, an inhibitor of the
STAT3 pathway that has been shown to markedly inhibit
p-STAT3 within immune cells (19), should theoretically inhibit
both TH17 cell generation and production of Tregs.
In this report, we show that WP1066 markedly inhibited
both natural and inducible Treg proliferation, and this may
account partially for the antitumor effects we observed in vivo
and the enhancement of cytotoxic T-cell response. Previous
studies in mice have shown that the ablation of Stat3 in the
hematopoietic system using the Mx1-Cre-loxP system was
accompanied by a reduction in the number of tumor-
infiltrating Tregs (31). STAT3 has been shown to be required
for both TGF-h and interleukin 10 production by CD4+ T cells
(32), factors necessary for the generation of tumor-associated
Tregs. Interleukin 2 has been shown to regulate FoxP3
expression in human CD4+CD25+ Tregs by STAT3 binding of
the first intron of the FoxP3 gene (33). The suppressor of
cytokine signaling-3 has been shown to inhibit STAT3 signaling
(34) and transcriptional activity (35, 36) but is deficient in
Tregs (37). The effect and mechanism of WP1066 on the
induction of Tregs is different from other known Treg
modulatory agents such as anti-CD25, which binds to the
surface of Tregs and disrupts the functional activity (38), and
anti-CTLA4, which confers resistance to Treg-mediated sup-
pression but not through a direct effect on Tregs (39). A
metronomic cyclophosphamide regimen has been shown to
selectively deplete numbers of Tregs (40), but it is not known
if this occurs via the STAT3 pathway. Regardless, these other
Treg modulators, at the doses administered, lack the significant
intrinsic direct tumor cytotoxicity properties possessed by
WP1066. Because Tregs are present within CNS melanoma,
the inhibitory effect of WP1066 on Tregs has clinical impli-
cations, especially considering that immunotherapeutic
approaches for melanoma have been disappointing (20).
WP1066 could potentially be used in combination with other
immunotherapeutic approaches such as dendritic cells (41),
Fig. 5. A, humoral responses were not induced inmice vaccinatedwith PEP-3-KLHandWP1066 but were induced, as anticipated, with PEP-3-KLHand CFA.B, cytotoxicity
of the B16EGFRvIII cells in vitro produced by splenocytes from mice vaccinated with PEP-3-KLHor with PEP-3-KLH plusWP1066.The splenocyte effector cells from mice
that were vaccinated with PEP-3-KLH induced minimal lysis. However, splenocyte effector cells from mice that were vaccinated with PEP-3-KLH plusWP1066 potently
enhanced EGFRvIII-specific lysis (P < 0.05). Columns, mean; bars, SD. C,WP1066 inhibits FoxP3 induction inTcells in peripheral blood and down-regulates FoxP3 in natural
Tregs. CD4+CD25-CD62Lhi naI« veTcells from C57BL/6J mice were stimulated by plate-bound anti-CD3 (2 ug/mL) and soluble anti-CD28 (2 ug/mL) in the presence of
TGFh1 (1ng/mL) and hIL2 (200 U/mL) with 0, 0.1, and1.0 mmol/LWP1066 for inducibleTregs (iTreg) differentiation; CD4+CD25+ Tcells (nTreg, naturalTregs) were
stimulated by plate-bound anti-CD3 (2 ug/mL) and soluble anti-CD28 (2 ug/mL) in the presence of hIL2 (200 U/mL) with 0, 0.1, and1.0 mmol/LWP1066. Ninety-six hours
after stimulation, the cells were analyzed for intracellular FoxP3 expression by flow cytometry.The percentage numbers for the indicated population are shown.
D, fluorescence-activated cell sorting staining of peritumoral and tumor tissue isolated from a patient with melanoma metastasis to the brain. CD4+ cells were gated
from the total cell population and plotted against FoxP3.
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peptide vaccination (21), or cytokine immunotherapy, such as
interleukin 2 or IFN.
In addition to immune modulatory properties, WP1066 also
acts directly upon the process of tumorgenesis and metastasis
by inhibiting the phosphorylation of STAT3 and the subse-
quent downstream molecules, such as survivin and c-Myc. For
human melanoma, unregulated c-Myc protein has also been
correlated with poor clinical outcome in both primary and
secondary diseases (42, 43), and RANTES has been shown to
enhance tumor formation (44). The inhibition of multiple
tumorigenic signaling pathways is highly desirable because of
the heterogeneity of cancers and the redundancy of cancer
growth signaling pathways. In the case of the B16 tumor cell
line, the changes in p-STAT3 levels were subtle after treatment
with WP1066. This could be because the Western blot analysis
was conducted on whole cell lysates, possibly causing changes
in nuclear p-STAT3 to go undetected. Alternatively, the 2 hours
of WP1066 treatment may not have been an optimal time for
assessing p-STAT3 levels. Most likely, a key mechanism in the
efficacy of WP1066 is its activity upon other cells within the
tumor microenvironment, such as T- and natural killer cells
(31, 45) and the cells or factors that support or propagate
angiogenesis, such as VEGF.
Patients with advanced malignancies are profoundly immu-
nosuppressed, and even if a systemic immune response could
be generated, it could be negated within the tumor microen-
vironment by a wide variety of factors, such as Tregs (24, 46,
47), immunosuppressive cytokines, and immunosuppressive
macrophages (24). We have recently shown that WP1066 can
modulate this tumor microenvironment, specifically by in-
creasing costimulatory molecule expression on immunosup-
pressive macrophages/microglia (19). Here, we have shown
that WP1066 can also inhibit the elaboration of immunosup-
pressive cytokines such as TGF-h and the Treg chemokine
MCP-1 (48) below the IC50, indicating that WP1066 has tumor
microenvironment modulatory properties that could overcome
some of these immunologic barriers in patients with solid
malignancies.
In mice previously treated with WP1066 who were rechal-
lenged with tumor cell inoculation, the longer median survival
time compared with naBve control animals showed a partial
protective immune effect. Yet, ultimately, these mice were not
long-term survivors, indicating that maintenance of the
immune effects of WP1066 will require sustained dosing if a
tumor recurs. Although WP1066 did not seem to enhance
humoral responses or induce immunologic memory that is
fully protective for tumor rechallenge, WP1066 inhibits
immunosuppressive cytokines, enhances costimulatory mole-
cule expression within the tumor microenvironment (19),
enhances cytotoxic T-cell responses, and inhibits the induction
of Tregs. Given its oral bioavailability, inherent immunomo-
dulatory properties, direct tumor cytotoxicity activity, ability
to enter the CNS, and efficacy against established CNS tumors,
WP1066 is a compelling agent for further development and
translation to applications for patients with intracerebral
melanoma metastasis—a major unmet clinical need. Marked
anticancer activity of WP1066 has also been shown against
head and neck carcinoma (13), pancreatic cancer (49), bladder
cancer (11), gliomas (12), B-cell non–Hodgkin’s lymphoma
and myeloma (14), and chronic myelogenous leukemia (50),
indicating that this class of compounds has broad potential for
treatment of oncological disease.
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